New York State Psychiatric Institute

117 total trials 35 currently recruiting 77 completed

Trial Pipeline

RECRUITING Phase 2

Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder

NCT05999240

RECRUITING Phase 4

Exercise and Olanzapine-samidorphan

NCT06740890

RECRUITING NA

Impacts of Cash Transfers on Child Neurodevelopment (Auxilio Brasil)

NCT05477901

RECRUITING NA

Effects of rTMS on Food Choice in Anorexia Nervosa

NCT05918835

RECRUITING Phase 2

Efficacy of Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use Disorder

NCT05011266

RECRUITING Phase 4

Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial

NCT05208190

RECRUITING Phase 1

Clinical Trials of Multivalent Opioid Vaccine Components

NCT04458545

ACTIVE NOT RECRUITING NA

Scaling up e-Connect in Juvenile Probation Settings

NCT05541926

ACTIVE NOT RECRUITING Phase 2

Glutamatergic Modulation as a Treatment for Depressive Symptoms Among Patients With Post-acute Sequelae of COVID (PASC): A Pilot Trial

NCT05690503

ACTIVE NOT RECRUITING Phase 1

Sublingual Dexmedetomidine for Treating Opioid Withdrawal

NCT05712707

ACTIVE NOT RECRUITING NA

Facilitating Opioid Care Connections

NCT04216719

ACTIVE NOT RECRUITING Phase 3

Facilitating Rapid Naltrexone Initiation

NCT03345173

COMPLETED NA

RCT of a Brief Video Intervention Targeting Peer Inclusion to Reduce Depression-related Stigma in Adolescents

NCT06360107

COMPLETED NA

Culturally Centering Medications for Opioid Use Disorder With American Indian and Alaska Native Communities

NCT04958798

COMPLETED NA

Leveraging Social Networks to Increase COVID-19 Testing Uptake

NCT04873401

COMPLETED

Mechanisms of Emotion Regulation Underlying Successful CBT in Depression

NCT04328103

COMPLETED NA

Treating Self Injurious Behavior: A Novel Brain Stimulation Approach

NCT04244786

COMPLETED Phase 1

D-serine Augmentation of Neuroplasticity

NCT03711500

COMPLETED NA

Improving Accessibility and Personalization of CR for Schizophrenia

NCT03576976

COMPLETED NA

Neural and Mobile Assessment OF Behavior Change Among Problem Drinkers

NCT03457077

COMPLETED Phase 1

Effect of Lorcaserin on Cannabis Withdrawal and Self-administration

NCT03253926

COMPLETED NA

Neuroimaging in Patients Undergoing TMS for Depression

NCT02974296

COMPLETED NA

Pilot Study of the Impact of Exercise on Hippocampal Function

NCT03036371

COMPLETED NA

Are Bright Lights and Regulated Sleep Effective Treatment for Depression?

NCT03010488

COMPLETED NA

Promoting Mother-Baby Bonding Through a Relaxation Routine During Pregnancy

NCT02943083

COMPLETED Phase 2

Treatment of Cannabis Use Disorder Among Adults With Comorbid Attention-Deficit/Hyperactivity Disorder

NCT02803229

COMPLETED

Reflective Function as a Mediator of Interpersonal Psychotherapy (IPT)

NCT02645929

COMPLETED NA

Development and Testing of a Smartphone Application to Reduce Substance Use and Sexual Risk Among Homeless Young Adults

NCT02530645

COMPLETED Phase 1

Medication-Assisted Treatment for Youth With Substance Use Disorders

NCT02593474

COMPLETED NA

Personalized Computerized Inhibitory Control Training for OCD

NCT02378896

COMPLETED NA

Biosignatures of Latuda for Bipolar Depression

NCT02239094

COMPLETED Phase 4

Prediction of Clinical Response to SSRI Treatment in Bipolar Disorder Using Serotonin 1A Receptor PET Imaging

NCT02473250

COMPLETED Phase 2

Open Label Trial of Rapastinel (Formerly GLYX-13) in Individuals With Obsessive-Compulsive Disorder

NCT02267629

COMPLETED Phase 4

Biomarker Assessment of Glutamatergic Target Engagement

NCT02134951

COMPLETED NA

Social Circumstances, Parenting Techniques, and Infant Development

NCT02121496

COMPLETED NA

Personalized and Scalable Cognitive Remediation Approaches

NCT01945333

COMPLETED Phase 2

Multicenter Trial of Combined Pharmacotherapy to Treat Cocaine Dependence

NCT01811940

COMPLETED Phase 2

Effects of Ibudilast on Oxycodone Self-administration in Opioid Abusers

NCT01740414

COMPLETED Phase 1

Open-Label Pilot Study of Lisdexamfetamine for Cocaine Dependence

NCT01486810

COMPLETED Phase 4

Combination Treatment Study for Memory Impairment and Depression

NCT01658228

COMPLETED NA

Imaging the Effects of Stimulant Medication on Emotional Lability in Patients With ADHD

NCT01415440

COMPLETED NA

Exercise, Age-Related Memory Decline, And Hippocampal Function

NCT01329653

COMPLETED Phase 1

Improved Strategies for Outpatient Opioid Detoxification

NCT01377610

COMPLETED Phase 2

Glutamatergic Modulation of Cocaine-related Deficits

NCT01790490

COMPLETED

Alprazolam and Eating Behavior in Anorexia Nervosa

NCT01411813

COMPLETED NA

Cognitive Benefits of Aerobic Exercise Across the Age Span

NCT01179958

COMPLETED Phase 2

Gabapentin for Abstinence Initiation in Alcohol Dependence

NCT01141049

COMPLETED Phase 4

Paroxetine/Bupropion in Depression With Suicide Attempt or Thoughts: fMRI Study

NCT01748955

COMPLETED NA

Web-delivery of Evidence-based, Psychosocial Treatment for Substance Use Disorders

NCT01104805

COMPLETED Phase 2

Enhancing Attention in Adults With Compulsive Hoarding

NCT01100268

COMPLETED Phase 2

Memantine Augmentation in Treatment-Resistant Adults With Obsessive-Compulsive Disorder

NCT00956085

COMPLETED

Examining Common Substrates of Eating and Alcohol Use Disorders

NCT01172210

COMPLETED Phase 3

Reinforcing Effects of Intranasal (IN) Buprenorphine Versus Buprenorphine/Naloxone

NCT01760473

COMPLETED NA

D-Cycloserine Augmentation to CBT With Exposure and Response Prevention in Adults and Adolescents With OCD

NCT01172873

COMPLETED Phase 2

Incorporating Patient Treatment Choice to Improve Treatment Retention in Depressed Hispanics

NCT00742573

COMPLETED Phase 2

Pilot Study of Minocycline (NPL-2003) in Adults With Obsessive-Compulsive Disorder (OCD)

NCT00728923

COMPLETED

The Development of an Eating Laboratory for Overweight Adolescents

NCT00764127

COMPLETED

Food Exposure Therapy in Anorexia Nervosa

NCT00755820

COMPLETED

Imaging the Dopamine Systems in Bulimia Nervosa

NCT01493362

COMPLETED Phase 2

Study of Adderall-XR for the Treatment of Adult Attention Deficit Hyperactivity Disorder and Cocaine Dependence

NCT00553319

COMPLETED Phase 2

Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Panic Disorder With Comorbid Major Depression

NCT00521352

COMPLETED Phase 3

Behavioral Naltrexone Therapy for Promoting Adherence to Oral Naltrexone vs Extended Release Injectable Depot Naltrexone

NCT00577408

COMPLETED Phase 1

Effect of Memantine Versus Bupropion on Smoking Relapse in Nicotine-Dependent Individuals - 3

NCT00136786

COMPLETED NA

Early Detection and Prevention of Mood Disorders in Children of Parents With Bipolar Disorder

NCT00338806

COMPLETED NA

Pre-Treatment Positron Emission Topography Scanning for Increasing Success in Antidepressant Treatment

NCT00456014

COMPLETED Phase 4

Duloxetine for Chronic Depression: a Double-blind Study

NCT00360724

COMPLETED Phase 4

Dichotic Listening as a Predictor of Medication Response in Depression

NCT00404755

COMPLETED Phase 2

Treatment of Depersonalization Disorder With Transcranial Magnetic Stimulation (TMS)

NCT00529217

COMPLETED Phase 2

Effect of Baclofen on Marijuana Withdrawal and Relapse

NCT00373295

COMPLETED Phase 1

Cognitive Behavioral Therapy Plus Motivational Interviewing for Treatment of Obsessive-Compulsive Disorder

NCT00316316

COMPLETED NA

Effectiveness of Culturally Based Congruent Care in Treating Hispanics With Major Depressive Disorder

NCT00247195

COMPLETED Phase 2

Effects of Aripiprazole on Cocaine Craving and Self-Administration

NCT00373880

COMPLETED NA

Effectiveness of Baclofen in the Treatment of People With Bulimia Nervosa or Binge Eating Disorder

NCT00320047

COMPLETED Phase 2

Dronabinol Treatment for Marijuana Addiction

NCT00217971

COMPLETED Phase 4

Antipsychotic Discontinuation in Alzheimer's Disease

NCT00417482

COMPLETED Phase 2

Atomoxetine for Treating Cocaine Abuse in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

NCT00218543

COMPLETED NA

Effectiveness of High Intensity Inpatient Versus Stepped Intensity Treatment for Anorexia Nervosa

NCT00815815

COMPLETED Phase 3

Women's Treatment for Trauma and Substance Use Disorders - 1

NCT00078156

COMPLETED NA

Improving Retention of Hispanics Receiving Antidepressant Therapy

NCT00057642

COMPLETED Phase 4

Optimizing Electroconvulsive Therapy for Depression

NCT00045916

COMPLETED NA

Cognitive Behavioral Therapy Plus Drug Treatment for Obsessive Compulsive Disorder

NCT00045903

COMPLETED Phase 4

Fluoxetine to Prevent Relapse and Enhance Psychological Recovery in Women With Anorexia Nervosa

NCT00288574

COMPLETED Phase 2

Venlafaxine to Reduce Cocaine Dependence in Depressed Individuals

NCT00249483

COMPLETED Phase 2

Opiate Dependence: Combined Naltrexone/Behavior Therapy - 1

NCT00238914

COMPLETED Phase 4

Comparing the Effects of Four Types of Electroconvulsive Therapy on Mood and Thinking in People With Depression

NCT00487500

COMPLETED Phase 2

Treatment of Adult Attention Deficit Hyperactivity Disorder (ADHD) in Methadone Patients - 1

NCT00061087

COMPLETED Phase 4

Prozac Treatment of Major Depression: Discontinuation Study

NCT00427128

COMPLETED Phase 2

A Laboratory Model for Heroin Abuse Medications - 8

NCT00000273

COMPLETED Phase 2

IV Cocaine Abuse: A Laboratory Model - 1

NCT00000212

Phase Distribution

PhaseTrial count
Phase 1 9
Phase 2 53
Phase 3 4
Phase 4 13

What the Pipeline for New York State Psychiatric Institute Shows

According to the ClinicalTrials.gov registry, New York State Psychiatric Institute is linked to 117 US clinical trials across every stage of research activity. Of those, 35 studies are currently recruiting — about 30% of the sponsor's indexed portfolio — and 77 are already marked complete, representing roughly 66% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.

The phase mix for New York State Psychiatric Institute reports 17 late-stage studies (Phase 3 and Phase 4 combined) and 62 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.

The top therapeutic focus area indexed for New York State Psychiatric Institute is Depression with 10 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial